3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
pembrolizumab
29
Cisplatin
19
Carboplatin
13
Cetuximab
12
Radiotherapy
10
Surveys and Questionnaires
9
Paclitaxel
9
Docetaxel
6
Radiotherapy, Intensity-Modulated
5
Surgical Procedures, Operative
4
Standard of Care
4
130-nm albumin-bound paclitaxel
4
dostarlimab
3
Therapeutics
3
Nivolumab
3
Fluorouracil
3
Cyclophosphamide
3
Chemoradiotherapy
3
Blood Specimen Collection
3
Albumin-Bound Paclitaxel
3
toripalimab
2
nimotuzumab
2
fludarabine
2
durvalumab
2
atezolizumab
2
abemaciclib
2
X-Rays
2
Taxes
2
Radiosurgery
2
Radiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled